DaVita Inc. (DVA) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup leans toward a beat — consensus is a manageable bar after Q1's large upside surprise, and the biggest swing factor is whether the Fresenius patient transfer tailwind and improving mortality trends translate into volume growth that meets or exceeds the raised 25–50 bps full-year guide.

Heading into Q2 2026, the bar for DaVita looks achievable but not trivially easy. Consensus adjusted operating income of ~$580M and EPS of ~$3.85 imply meaningful sequential improvement from Q1's $482M OI, consistent with management's guidance that the remaining three quarters would be roughly evenly split — but Q1 benefited from ~$50M of outperformance, roughly half of which was timing, so the market is already pricing in a normalization. Management's tone on the Q1 call was constructively confident: full-year adjusted OI guidance was raised $40M at the midpoint to $2.15–$2.25B, volume growth was upgraded from flat to +25–50 bps, and the ACA enhanced premium tax credit headwind is tracking better than the embedded $40M assumption — all of which sets a positive tone heading into Q2. Estimate revisions have been stable-to-slightly-positive since the Q1 print, with the FY2026 adjusted OI consensus sitting at ~$2.24B, near the midpoint of guidance, suggesting the Street is not yet pricing in a second consecutive guidance raise. The stock has surged ~49% since the Q1 earnings date (from $157 to ~$234), dramatically outperforming XLV (+12%) and the S&P 500 (+5%), which means a meaningful beat is already partially priced in and the stock's reaction function is asymmetric — a miss or cautious tone on ACA/commercial mix could be disproportionately punished. The key wildcard is the pace of Fresenius clinic closure patient transfers: management guided that roughly half of the transfer benefit would arrive in Q2, and any shortfall there — or an earlier-than-expected deterioration in commercial payer mix from ACA enrollment shifts — could pressure both RPT and volume simultaneously.

Bar: Consensus adjusted OI of ~$580M is a moderate bar — above Q1's $482M but consistent with management's even-split phasing guidance. The Street appears to be modeling a clean quarter without a second timing benefit.

Guidance/Tone: Management was notably more confident on the Q1 call, raising and narrowing OI guidance, upgrading volume growth, and signaling the ACA headwind is tracking better than feared. No post-earnings guidance revisions have been issued since May 5.

Estimate Trajectory: Revisions have been stable since the Q1 print. FY2026 consensus OI of ~$2.24B sits near the guidance midpoint, implying the Street is not yet embedding a second raise — a potential source of upside if Q2 execution is clean.

Stock Setup: DVA has re-rated sharply post-Q1, up ~49% vs. the earnings date close. The stock is trading well above consensus analyst price targets (~$203–$217 range), suggesting sentiment has run ahead of fundamental revisions. A beat is partially priced in.

Wildcard: The pace and magnitude of Fresenius patient transfer completions in Q2, combined with the ACA commercial mix trajectory — if either disappoints, RPT and volume could both miss simultaneously, creating outsized downside risk given the elevated stock price.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a moderate bar — adjusted OI of ~$580M implies solid sequential improvement but is consistent with management's even-split phasing guide. Treatment volume growth is the bigger swing factor: the Q2 consensus of +0.40% YoY would mark the first positive quarter in over a year, and any shortfall there cascades directly into both revenue and margin.

Table 1 — Q2 2026 Current Quarter Snapshot

Sources: Visible Alpha Consensus and Actuals Data; DaVita Q1 2026 Earnings Call (May 5, 2026). All consensus figures as of August 3, 2026.

Table 2 — Beat/Miss History: Last 8 Quarters (Top 2 KPIs)

KPI 1: Adjusted Operating Income (Operating OI)

KPI 2: Adjusted Diluted EPS

Pattern: Of the four quarters with available VA consensus data, DVA beat on adjusted OI and EPS in three of four quarters, with the sole miss in Q3 2025 driven by the cyber incident legacy effects and elevated mortality — a one-time disruption that management has since characterized as fully resolved. The Q1 2026 beat was unusually large (+11% on OI, +21% on EPS), setting a high bar for Q2 expectations.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised and narrowed on the Q1 2026 call (May 5) — the most significant post-Q4 update. No further revisions have been issued since then, and management's tone remains constructively confident, with the ACA headwind tracking better than the embedded $40M assumption.

Source: DaVita Q1 2026 Earnings Call transcript (May 5, 2026); Visible Alpha Consensus Data.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have been stable-to-slightly-positive since the Q1 print — the Street has absorbed the guidance raise but is not yet embedding a second consecutive raise. The FY2026 OI consensus of ~$2.24B sits just above the guidance midpoint, suggesting modest upside cushion if Q2 execution is clean and the ACA headwind continues to track better than feared.

Estimates have been remarkably stable since the Q1 print — the Street absorbed the guidance raise immediately and has not revised further in either direction. The FY2026 OI consensus of ~$2.24B sits ~2% above the guidance midpoint, implying a modest cushion if Q2 is clean. The key risk is that RPT consensus (+2.4% YoY) is already slightly above the +1–2% guidance range, meaning any ACA-driven commercial mix deterioration in Q2 could create a negative RPT surprise even if volume holds.

Source: Visible Alpha Consensus and Actuals Data; DaVita Q1 2026 Earnings Call (May 5, 2026).

5. Stock Performance

Key Takeaway: DVA has surged ~+49% since the Q1 2026 earnings date (May 5, 2026), dramatically outperforming XLV (+12%) and the S&P 500 (+5%). The move has been almost entirely sentiment and multiple re-rating driven — the stock has run well past consensus analyst price targets ($203–$217 range), suggesting the market is pricing in a sustained beat cycle rather than just the Q1 upside.

DVA vs XLV (Health Care ETF) vs S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (May 5, 2026). Source: Yahoo Finance.

DVA opened at $157.04 on May 5, 2026 (Q1 earnings day) and closed at $233.68 on August 4, 2026 — a gain of +$76.64 (+48.8%) vs. XLV +11.7% and SPY +4.7% over the same period. The initial gap-up on May 6 (from $157 to $194, +23%) captured the immediate Q1 beat and guidance raise reaction. The stock continued to grind higher through June and July, driven by continued positive sentiment around the Fresenius transfer tailwind, improving mortality trends, and the broader healthcare sector re-rating. Analyst price target upgrades followed the Q1 print (TD Cowen: $144→$201; Truist: $158→$205; Barclays: $194→$218; Truist again: $205→$250 in July), but the stock has now run past even the most bullish targets, suggesting the market is pricing in a sustained beat cycle. The Zacks downgrade from Strong-Buy to Hold on July 6 reflects this dynamic. Sector ETF XLV also outperformed the S&P 500 over this period, providing a modest tailwind, but DVA's outperformance vs. XLV of ~+37 percentage points is almost entirely company-specific.

Source: Yahoo Finance / Stock Price Data.

6. Peer Commentaries — Q2 2026 Read-Throughs

Key Takeaway: Q2 2026 peer earnings calls from HCA, THC, UHS, CHE (Vitas), and OPCH confirm the two most important read-throughs for DVA: (1) the ACA enhanced premium tax credit expiration is driving a near-one-for-one migration from exchange-insured to uninsured across the hospital sector, which is a meaningful RPT headwind for DVA's commercial mix; and (2) underlying healthcare demand and patient volumes remain healthy, supporting DVA's volume recovery thesis. The ACA read-through is the most actionable negative signal; the volume/demand read-through is a modest positive.

Note: All commentaries below are from Q2 2026 earnings calls (reported July 24–29, 2026), covering the same calendar quarter as DVA's upcoming Q2 2026 report. These are current-quarter read-throughs, not prior-quarter results.

HCA Healthcare (HCA) — Q2 2026 Earnings Call (July 24, 2026)

ACA / Enhanced Premium Tax Credit Expiration — Worse Than Expected: HCA reported that the expiration of enhanced premium tax credits at year-end 2025 drove a near-one-for-one migration from exchange-insured to uninsured status. Exchange-covered adjusted admissions fell 15% YoY in Q2. HCA's original assumption was that 80–85% of patients losing exchange coverage would become uninsured; actual data shows it is closer to 100%. The payer mix shift created an unfavorable EBITDA impact of approximately $400M in Q2 (including a $75M upward revision to the Q1 estimate). Three divisions (Gulf Coast, North Florida, South Atlantic) accounted for ~50% of the total impact, with exchange admission declines of 25–28% in those markets.

DVA Read-Through: This is a direct negative read-through for DVA's commercial payer mix. DVA's Q1 2026 commercial mix was roughly flat sequentially and better than feared, but management explicitly warned that ACA-driven commercial mix deterioration was expected to materialize later in the year. HCA's Q2 data confirms that deterioration is real and accelerating in Q2 — the same quarter DVA is reporting. This increases the probability that DVA's RPT comes in at or below the low end of the +1–2% guidance range, and that the $40M ACA headwind assumption may prove conservative in the wrong direction (i.e., the headwind could be larger than $40M if commercial mix deterioration is more severe than modeled).

Underlying Demand Remains Healthy: Excluding exchange-related volume, HCA's insured volumes were solid, with same-facility admissions +2.5% and ER visits +3.6%. Management maintained its long-term demand growth assumption of 2–3% and noted that demographic trends in its markets (Florida, Texas, etc.) are as positive or more positive than during the COVID migration period. Emergency inpatient surgery volumes were up 2% YoY.

DVA Read-Through: Positive for DVA's underlying treatment volume thesis. Healthy hospital volumes and ER activity support the view that ESRD patient demand is stable, and that the Fresenius clinic closure patient transfers are occurring in an environment of adequate underlying demand.

Tenet Healthcare (THC) — Q2 2026 Earnings Call (July 24, 2026)

ACA Exchange Erosion Accelerating: THC reported exchange revenues down 17% YoY in Q2, representing ~5.5% of consolidated net operating revenues. Exchange volume admissions fell ~13.5%. The company observed a "pretty consistent conversion from exchange patient volume into uninsured, on a pretty much 1 to 1 basis." The exchange revenue decline created a ~$65M revenue headwind in Q2. THC expects these trends to "roughly continue into Q3 and Q4." The highest-impact states are Florida, Arizona, Michigan, South Carolina, and Texas.

DVA Read-Through: Consistent with HCA's read-through — the ACA commercial mix headwind is real, broad-based, and expected to persist through the rest of 2026. For DVA, this reinforces the risk that the $40M ACA headwind assumption embedded in guidance may be understated, and that RPT growth in Q2 will be pressured relative to Q1's elevated +4% YoY print.

Strong Underlying Business Performance: Despite the exchange headwind, THC delivered consolidated adjusted EBITDA growth of +16.3% YoY and adjusted diluted EPS of $6.12 (+52% YoY). Same-hospital inpatient adjusted admissions rose 2.6% sequentially. Management raised revenue, adjusted EBITDA, and cash flow guidance for FY2026, citing strong fundamental business performance and effective cost management.

DVA Read-Through: Positive signal that healthcare operators can navigate the ACA headwind through cost discipline and volume strength — consistent with DVA's own operational playbook.

Universal Health Services (UHS) — Q2 2026 Earnings Call (July 28, 2026)

ACA Impact In-Line with Expectations: UHS estimated a ~$20M pre-tax impact from exchange trends in Q2, in line with expectations. Exchange volumes declined ~15% vs. Q2 2025. UHS noted that "virtually everyone who lost their exchange coverage became an uninsured patient" — the original assumption that 10–20% would replace coverage with other commercial insurance did not materialize. Full-year pre-tax impact is now expected to be ~$85M (up from $75M prior guidance). Payer mix trends were otherwise consistent with recent quarters, with stronger growth in Medicare and managed Medicare.

DVA Read-Through: The UHS data point that exchange patients are converting to uninsured at nearly 100% (vs. the original 10–20% assumption for commercial replacement) is the most important read-through for DVA's commercial mix. DVA's Q1 commercial mix was flat sequentially, but UHS's Q2 data suggests the deterioration is now materializing in earnest. This is a meaningful risk to DVA's RPT in Q2.

Acute Care Volume Rebound: UHS reported same-facility acute care adjusted admissions +2.9% YoY in Q2, improving sequentially from Q1. ER visits +4%. Surgical volumes were slightly muted (-0.8%) but showed sequential improvement. Management fine-tuned full-year acute care volume guidance to 1.5–2.5% (50 bps lower at midpoint) to reflect year-to-date trends and continued shift of elective procedures to alternate sites.

DVA Read-Through: Broadly positive for DVA's treatment volume thesis. Healthy acute care demand supports the view that ESRD patients are accessing care, and the sequential improvement in volumes is consistent with DVA's own volume recovery narrative.

Chemed / Vitas Healthcare (CHE) — Q2 2026 Earnings Call (July 29, 2026)

Strong Patient Volume Growth — Mortality Trends Favorable: Vitas (CHE's hospice subsidiary) reported Q2 2026 admissions of 19,125, up 9% YoY. Average daily census was 23,687 patients (+6.1% YoY), and total patient census exceeded 24,000 for the first time in Vitas history. Management stated performance "exceeded even the high end of our expectations" and that Vitas has "returned to a normalized rate of growth." Full-year 2026 ADC growth guidance was raised to 5.75–6.25% (from 4.5–5.5%). Management described the level of growth as "very sustainable" and characterized traditional growth rates as "low double digits."

DVA Read-Through: This is a nuanced but important read-through. Vitas's strong hospice admission growth and improving mortality trends are a mild positive for DVA's volume thesis — better mortality in the broader population is consistent with DVA's own commentary that underlying mortality trends improved in Q1 2026, supporting the volume guidance upgrade. However, strong hospice growth also implies that some ESRD patients who might otherwise have remained on dialysis are transitioning to hospice care, which is a modest structural headwind to DVA's treatment volume. On balance, the improving mortality signal is the more relevant read-through.

Labor Costs Well-Controlled: Vitas kept hospice labor costs below budget while achieving ADC growth above expectations, maintaining full-time equivalents below budgeted targets. Adjusted EBITDA (ex-Medicare cap) was $80.6M (+20.6% YoY) with an 18.2% margin. Full-year EBITDA margin guidance raised to 19–19.5% (from 18–18.5%).

DVA Read-Through: Positive signal that healthcare labor markets remain manageable — consistent with DVA's own commentary on labor productivity improvements in Q1 2026.

Option Care Health (OPCH) — Q2 2026 Earnings Call (July 29, 2026)

Home/Alternate Site Care Demand Remains Strong: OPCH reported high single-digit organic growth in its acute therapy portfolio, with sequential and YoY growth across all key therapeutic categories. The company expanded its ambulatory infusion clinic footprint by five new facilities in Q2, with clinic visits growing more than 20% YoY. Management noted that payer conversations "continue to be productive" and that OPCH is "on the right side of the cost quality equation."

DVA Read-Through: Broadly positive for the home/alternate site care thesis. Strong demand for home infusion and outpatient care is consistent with DVA's IKC value-based care model, which aims to manage ESRD patients in lower-cost settings. The site-of-care shift trend that OPCH is benefiting from is the same macro tailwind that underpins DVA's IKC growth strategy.

AI and Technology Investment in Healthcare: OPCH highlighted AI deployment for nursing optimization and scheduling efficiency, expecting AI to "reduce the cost of health care while improving clinician efficiency." The company is using AI to make nursing resources more productive, reducing the need for incremental headcount.

DVA Read-Through: Consistent with DVA's own AI investment narrative. DVA has explicitly stated that AI will be a net cost through 2026 and much of 2027, with near-term benefits in software development productivity and revenue operations. OPCH's commentary suggests the industry is at a similar stage of AI adoption, validating DVA's investment thesis but also confirming that near-term financial benefits remain limited.

Peer Read-Through Summary

Sources: HCA Q2 2026 Earnings Call (July 24, 2026); THC Q2 2026 Earnings Call (July 24, 2026); UHS Q2 2026 Earnings Call (July 28, 2026); CHE Q2 2026 Earnings Call (July 29, 2026); OPCH Q2 2026 Earnings Call (July 29, 2026).

7. Material News & Developments

Key Takeaway: The most important development since the Q1 print is the confirmation from multiple hospital peers that the ACA enhanced premium tax credit expiration is driving a near-one-for-one migration to uninsured status — a direct RPT headwind for DVA that management had flagged but the market may not have fully priced in. The Berkshire Hathaway share repurchase and continued Fresenius clinic closures are the key company-specific positives.

• May 5, 2026 — Q1 2026 Earnings Beat & Guidance Raise: DVA reported Q1 2026 adjusted OI of $482M (vs. ~$434M consensus, +11% beat) and adjusted EPS of $2.87 (vs. ~$2.37 consensus, +21% beat). Full-year adjusted OI guidance raised $40M at midpoint to $2.15–$2.25B; adjusted EPS guidance raised to $14.10–$15.20; volume growth guidance upgraded from flat to +25–50 bps. Stock gapped up ~23% the following day.
• May 5, 2026 — Berkshire Hathaway Share Repurchase: DVA repurchased shares directly from Berkshire Hathaway during Q1 2026 pursuant to a pre-existing repurchase agreement, contributing to a total of approximately 5 million shares repurchased in and shortly after the quarter. This is a meaningful capital return signal and reduces the float.
• May 6, 2026 — BofA Securities 2026 Health Care Conference: DVA participated in the BofA Health Care Conference, providing an opportunity for management to reiterate Q1 messaging to institutional investors. No material guidance changes were disclosed.
• May–June 2026 — Fresenius Clinic Closures Largely Complete: Management guided on the Q1 call that approximately 100 Fresenius clinic closures were expected to be largely complete by end of Q2 2026, with the annualization point around end of April/May. DVA expected to realize roughly two-thirds of a year's worth of new starts from these transfers, with ~half arriving in Q1 and ~half in Q2. This is a key volume tailwind for Q2 that the Street is modeling at +40 bps YoY treatment growth.
• May–July 2026 — Analyst Price Target Upgrades: Multiple analysts raised price targets following the Q1 beat: TD Cowen ($144→$201, Hold, May 11); Truist ($158→$205, Hold, May 8); UBS (upgraded to Buy, $126→$220, May 7); Barclays ($194→$218, Equal Weight, July 8); Truist ($205→$250, Hold, July 14). Consensus rating remains Hold (5 Hold, 2 Buy, 1 Sell) with average PT of ~$216. Stock has run past all but the most recent Truist target.
• July 6, 2026 — Zacks Downgrade (Strong-Buy → Hold): Zacks Research downgraded DVA from Strong-Buy to Hold, reflecting the stock's significant run-up past fair value estimates. Implication: sentiment has shifted from undervalued to fairly-to-fully valued at current levels, increasing the bar for a positive stock reaction on Q2 results.
• July 21, 2026 — Q2 2026 Earnings Call Scheduled: DVA announced the Q2 2026 investor conference call for August 4, 2026 (after market close). No pre-announcement or guidance update was issued alongside the scheduling announcement — consistent with management's practice of reserving guidance updates for earnings calls.
• July 24–29, 2026 — Hospital Peer Q2 Earnings (ACA Read-Through): HCA, THC, UHS, CHE, and OPCH all reported Q2 2026 results. The consistent theme across hospital peers is that the ACA enhanced premium tax credit expiration is driving a near-one-for-one migration from exchange-insured to uninsured, with exchange volumes down 13–17% YoY across the sector. This is a direct negative read-through for DVA's commercial payer mix and RPT in Q2. See Section 6 for full peer commentary analysis.
• Ongoing — CMS Phosphate Binder Bundle Inclusion (2027 Preliminary Rule): Management noted on the Q1 call that the CMS preliminary rule on phosphate binder bundle inclusion was expected around end of June or early July 2026. The 2025 OI contribution from phosphate binders was approximately the same magnitude as the prior year's disclosed figure, with a similar contribution expected in 2026. The 2027 outlook is uncertain pending the CMS rule. This is a potential binary event for DVA's 2027 earnings power.
• Ongoing — AI & Technology Investment: DVA continues to invest in AI and digital infrastructure (Schedule Hub for dynamic staffing, revenue operations tools). Management has explicitly guided that AI will be a net cost through 2026 and much of 2027. G&A costs per treatment were up 13% YoY in Q1 due to technology investments. This is a known headwind to near-term margins but a potential long-term efficiency driver.

8. Insider Transaction Activity

Key Takeaway: The most notable transaction is Warren Buffett / Berkshire Hathaway's sale of ~1.22M shares on May 1, 2026 (filed May 5), consistent with the pre-existing repurchase agreement with DVA. CEO Javier Rodriguez sold ~69K shares in mid-June via open-market transactions — the size and discretionary nature of these sales is worth monitoring, though they follow a large post-earnings stock gain. No open-market buys from insiders — the absence of insider buying at current elevated prices is a mild cautionary signal.

Summary: The insider transaction picture is mixed but not alarming. The Berkshire Hathaway sale (1.22M shares) was pursuant to a pre-existing repurchase agreement with DVA and should be viewed as a capital return mechanism rather than a bearish signal. The CFO's sale of 51K shares two days post-Q1 earnings and the CEO's combined sale of ~69K shares in mid-June are the most notable discretionary transactions — both occurred after the stock had already surged 25–35% from the earnings date, suggesting profit-taking rather than a negative fundamental view. The CLO's sale was pre-scheduled under a 10b5-1 plan. Critically,

no insiders have made open-market purchases since the Q1 earnings date, which is a mild cautionary signal at current elevated price levels (~$234 vs. consensus PT of ~$216).

Source: SEC Form 4 filings / Insider Transaction Data.